INT55513

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1993
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 19
Total Number 20
Disease Relevance 2.37
Pain Relevance 5.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Foxm1) embryo development (Foxm1) DNA binding (Foxm1)
transcription factor binding (Foxm1) cytoplasm (Foxm1)
Anatomy Link Frequency
endocrine cell 3
brain 2
skeletal muscle 1
CNS 1
cortex 1
Foxm1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 40 99.96 Very High Very High Very High
Cannabinoid receptor 36 99.40 Very High Very High Very High
Central nervous system 27 99.34 Very High Very High Very High
Antinociceptive 1 99.20 Very High Very High Very High
Serotonin 40 99.08 Very High Very High Very High
Hippocampus 26 98.86 Very High Very High Very High
sodium channel 27 98.72 Very High Very High Very High
Potency 31 98.64 Very High Very High Very High
agonist 168 98.20 Very High Very High Very High
Morphine 14 97.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Injury 26 100.00 Very High Very High Very High
Neuroleptic Malignant Syndrome 38 95.92 Very High Very High Very High
Contact Dermatitis 29 93.44 High High
INFLAMMATION 77 92.48 High High
Hyperglycemia 8 92.00 High High
Shock 7 85.84 High High
Diabetes Mellitus 24 82.08 Quite High
Hypothermia 3 69.20 Quite High
Catalepsy 2 66.56 Quite High
Hypertrophy 4 50.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Here, we show that Foxm1 and some of its transcriptional targets were upregulated within islets following PPx during the period of peak regeneration and that endocrine cell proliferation and regeneration of ?
Foxm1 Binding (some) of in endocrine cell
1) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.25 Pain Relevance 0
Interestingly, after PPx FoxM1?
FoxM1 Binding (after) of
2) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.05 Pain Relevance 0
Here, we show that Foxm1 and some of its transcriptional targets were upregulated within islets following PPx during the period of peak regeneration and that endocrine cell proliferation and regeneration of ?
Foxm1 Binding (targets) of in endocrine cell
3) Confidence 0.37 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.25 Pain Relevance 0
These observations, taken together, would imply that the "win-stay, lose-shift" strategy may interact with the discrimination of the drug effects.
win Binding (interact) of
4) Confidence 0.35 Published 1997 Journal Life Sci. Section Abstract Doc Link 9307049 Disease Relevance 0.32 Pain Relevance 0.44
To determine whether FoxM1 is necessary for endocrine cell regeneration following pancreatic injury, FoxM1?
FoxM1 Binding (injury) of in endocrine cell associated with injury
5) Confidence 0.32 Published 2008 Journal Diabetes Section Body Doc Link PMC2570403 Disease Relevance 0.19 Pain Relevance 0
In previous studies it was shown that the structurally dissimilar compounds delta 9-THC, CP 55,940 and WIN 55,212 produced more or less the same pharmacological effects and interacted with the same cannabinoid receptor.
WIN Binding (interacted) of associated with cannabinoid receptor
6) Confidence 0.31 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7996450 Disease Relevance 0.14 Pain Relevance 0.26
In rat brain synaptic membranes, [(3)H]WIN 17317-3 binds reversibly and saturably to a single class of high-affinity sites (K(d) 2.2 +/- 0.3 nM; B(max) 5.4 +/- 0.2 pmol/mg of protein).
WIN Binding (binds) of in brain
7) Confidence 0.31 Published 1999 Journal Biochemistry Section Abstract Doc Link 10460170 Disease Relevance 0 Pain Relevance 0.29
WIN 17317-3 interacts similarly with skeletal muscle sodium channels but is a weaker inhibitor of the cardiac sodium channel.
WIN Binding (interacts) of in skeletal muscle associated with sodium channel
8) Confidence 0.31 Published 1999 Journal Biochemistry Section Abstract Doc Link 10460170 Disease Relevance 0 Pain Relevance 0.59
The potency and rank order of effectiveness of these agents in affecting [(3)H]WIN 17317-3 binding is consistent with their known abilities to modify sodium channel activity.
WIN Binding (binding) of associated with sodium channel and potency
9) Confidence 0.31 Published 1999 Journal Biochemistry Section Abstract Doc Link 10460170 Disease Relevance 0 Pain Relevance 0.53
Animals treated with 5 mg/kg of MDMA alone (M5) exhibited higher levels than those treated with saline (Sal) (p < 0.05). 5-HIAA levels had significant effects on the interaction of the variables MDMA dose × WIN dose [F(4,44) = 3.271; p < 0.01].
WIN Binding (interaction) of
10) Confidence 0.27 Published 2010 Journal Behav Brain Funct Section Body Doc Link PMC2858089 Disease Relevance 0 Pain Relevance 0.30
In the hippocampus, serotonin concentration had significant effects on the interaction of the variables MDMA dose × WIN dose [F(4,46) = 2.828; p < 0.03].
WIN Binding (interaction) of in hippocampus associated with hippocampus and serotonin
11) Confidence 0.27 Published 2010 Journal Behav Brain Funct Section Body Doc Link PMC2858089 Disease Relevance 0 Pain Relevance 0.27
L of reconstituted lyophilized MPM, 100 ?
MPM Binding (lyophilized) of
12) Confidence 0.26 Published 2007 Journal J Inflamm (Lond) Section Body Doc Link PMC1845142 Disease Relevance 0.66 Pain Relevance 0.12
WIN 55,212-2 (1 microM) inhibited the electrically evoked tritium overflow from mouse brain cortex slices preincubated with [3H]choline by 49%. [3H]WIN 55,212-2 binding to mouse cortex membranes was inhibited by CP-55,940, SR 141716 and WIN 55,212-2 (pKi=9.30, 8.70 and 8.19, respectively) but not by the auxiliary drugs indalpine, metitepine and tetrodotoxin (pKi<4.5). [35S]GTPgammaS binding was increased by WIN 55,212-2 (maximum effect of 80%, pEC50=6.94) but not affected by WIN 55,212-3.
WIN Binding (binding) of in cortex associated with tetrodotoxin
13) Confidence 0.23 Published 2000 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 10651142 Disease Relevance 0 Pain Relevance 0.52
The effects of cannabinoid receptor ligands on the electrically evoked tritium overflow from mouse brain cortex slices preincubated with [3H]choline and on the binding of [3H]WIN 55,212-2 and [35S]GTPgammaS to mouse brain cortex membranes were examined as well.
WIN Binding (binding) of in brain associated with cannabinoid receptor
14) Confidence 0.23 Published 2000 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 10651142 Disease Relevance 0 Pain Relevance 0.56
A binding assay for WIN 55212-2, an aminoalkylindole (AAI) with antinociceptive activity in rodents, is described. [3H]WIN 55212-2 bound to rat cerebellar membranes with a Kd of 2 nM and a maximum binding of 1.2 pmol/mg of protein.
WIN Binding (bound) of associated with antinociceptive
15) Confidence 0.17 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8450470 Disease Relevance 0 Pain Relevance 0.21
In CB(1)(+/+) membranes, SR141716A inhibited only 84% of anandamide and 67% of WIN55212-2 stimulated [(35)S]GTP gamma S binding with an affinity appropriate for mediation by CB(1) receptors (K(B) approximately 0.5 nM).
WIN55212-2 Binding (binding) of
16) Confidence 0.01 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11408610 Disease Relevance 0 Pain Relevance 0.41
In CB(1)(-/-) membranes, SR141716A affected both basal and anandamide- or WIN55212-2-induced stimulation of [(35)S]GTP gamma S binding only at concentrations greater than 1 microM.
WIN55212-2 Binding (binding) of
17) Confidence 0.01 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11408610 Disease Relevance 0 Pain Relevance 0.26
Moreover, some of these same CNS regions also showed significant binding of [(3)H]WIN55212-2, but not [(3)H]CP55940.
WIN55212-2 Binding (binding) of in CNS associated with central nervous system
18) Confidence 0.01 Published 2001 Journal Mol. Pharmacol. Section Abstract Doc Link 11408610 Disease Relevance 0 Pain Relevance 0.70
Similarly, analogs of the commercially available neurokinin receptor antagonists, WIN 62,577 and WIN 51,708 (Fig. 6), as well as the parent compounds themselves, were found to interact with gallamine and strychnine in a non-competitive manner, whilst competing with staurosporine and KT5720 [63].
WIN Binding (interact) of associated with antagonist
19) Confidence 0.01 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2656816 Disease Relevance 0.26 Pain Relevance 0.05
Similarly, analogs of the commercially available neurokinin receptor antagonists, WIN 62,577 and WIN 51,708 (Fig. 6), as well as the parent compounds themselves, were found to interact with gallamine and strychnine in a non-competitive manner, whilst competing with staurosporine and KT5720 [63].
WIN Binding (interact) of associated with antagonist
20) Confidence 0.01 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2656816 Disease Relevance 0.26 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox